Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099788 · ClinicalTrials.gov registry record · Phase 3
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,560
- Enrollment target
NCT00099788: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT00099788 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 6,560 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (750% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00099788, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,560 participants
- Enrollment target
Study Summary
MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately 5,500 patients with non-ST elevation acute coronary syndromes (ACS) treated with standard therapy. The primary efficacy endpoint in MERLIN-TIMI 36 is time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST elevation ACS receiving standard therapy. The study also evaluates the safety of long-term treatment with ranolazine compared to placebo.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,560 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
What the finished NCT00099788 record still lists
NCT00099788 is an interventional study that assigns participants to a tested intervention. Its 6,560 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (750% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00099788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00099788 about?
NCT00099788 is a clinical study titled "Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes". MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately 5,500 patients with non-ST elevation acute coronary syndromes (ACS) treated...
What is the current status of trial NCT00099788?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,560 participants. The study started on 2004-10. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00099788?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT00099788?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00099788's enrollment target sits among peer trials
6,560 35th of 2000 higher than 1,966 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05143697 · 6,600 participants · NA
Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids
- NCT05515224 · 6,600 participants · NA
5-Cog 2.0: A Pragmatic Clinical Trial
- NCT05369429 · 6,516 participants · NA
My Wellbeing Guide: a Novel Tool for Managing Stress and Improving Quality of Life
- NCT06272045 · 6,618 participants · NA
Early Intervention to Promote Cardiovascular Health of Mothers and Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia